Validation of an enhanced International Prognostic Index (NCCN-IPI) in an Asian cohort of patients with diffuse large B cell lymphoma

Ann Hematol. 2015 Jun;94(6):1063-5. doi: 10.1007/s00277-014-2293-8. Epub 2015 Jan 7.

Authors

Cih-En Huang¹, Yi-Yang Chen, Chang-Hsien Lu, Pin-Tsung Chen, Kuan-Der Lee, Chih-Cheng Chen

Affiliation

¹ Division of Hematology Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.

PMID: 25563598
DOI: 10.1007/s00277-014-2293-8

No abstract available

Publication types

Letter
Validation Study

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Asian People / ethnology*
Cohort Studies
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Female
Humans
Internationality*
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / ethnology*
Male
Middle Aged
Prednisone / administration & dosage
Prognosis
Rituximab
Survival Rate / trends
Vincristine / administration & dosage

Substances

Antibodies, Monoclonal, Murine-Derived
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone